MedPath

AIM VACCINE

AIM VACCINE logo
🇨🇳China
Ownership
Public
Established
2011-11-09
Employees
1.5K
Market Cap
-
Website
http://www.aimbio.com
Introduction

Le Meridien Vaccine is a large-scale private vaccine group with a full industry chain in China. Its business covers the entire industry value chain from R&D to manufacturing to commercialization. It obtained batches of about 60 million doses in 2020, achieving sales of vaccine products to 31 provinces, autonomous regions and municipalities directly under the Central Government of China. Le Meridien has five vaccine companies that have proven human vaccine platform technology, which greatly guarantees the speed and flexibility of the company's development. Currently, the company has 8 commercial vaccines for 6 disease fields and 23 innovative vaccines under development for 13 disease fields. The products in production and development cover all of the world's top ten vaccine products (based on global sales in 2020).

Through ten years of development, the company has developed an inclusive and pioneering business model and corporate culture, through which it has been able to continuously expand and optimize its existing business. Currently, four licensed vaccine manufacturers are wholly owned, namely Le Meridien, Emmy Conhuai, Emmy Weixin, and Rongan Biotech. It owns 3 research institutes, of which the R&D center, Le Meridien Explorer, which was built in 2018, focuses on providing technical support for early and cutting-edge research by R&D departments in various factories. Le Meridien acquired Zhuhai Lifanda Biotechnology Co., Ltd. in 2021. The company is one of only 3 domestic companies to obtain approval for clinical trials of the mRNA COVID-19 vaccine, and has an independent mRNA production and drug delivery technology platform.

Le Meridien Vaccine Group has always adhered to the mission of “making vaccines of conscience and living a healthy world” and strictly controls the quality of vaccines. The company is equipped with a professional and dedicated sales team composed of more than 100 members with an average of more than 10 years of experience in drug or vaccine sales. The core business leadership team has an average of 12 years of vaccine commercialization experience for multinational pharmaceutical companies, and has excellent results in marketing major international vaccines (including the world's first HPV, IPV, and dTAP-IPV-Hib). The products currently on sale mainly include recombinant hepatitis B vaccine (Hanson's yeast), freeze-dried human rabies vaccine (Vero cells), hepatitis A inactivated vaccine (human diploid cells), live attenuated mumps vaccine, bivalent renal syndrome hemorrhagic fever inactivated vaccine (Vero cells), and ACYW135 group meningococcal polysaccharide vaccine (MPSV4).

Clinical Trials

13

Active:6
Completed:1

Trial Phases

4 Phases

Phase 1:3
Phase 2:2
Phase 3:3
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Not Applicable
5 (38.5%)
Phase 1
3 (23.1%)
Phase 3
3 (23.1%)
Phase 2
2 (15.4%)

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Phase 2
Active, not recruiting
Conditions
SARS-CoV-2
First Posted Date
2023-07-11
Last Posted Date
2023-11-24
Lead Sponsor
AIM Vaccine Co., Ltd.
Target Recruit Count
450
Registration Number
NCT05939648
Locations
🇨🇳

Chuanmiao Liu, Bangbu, Anhui, China

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

Phase 1
Active, not recruiting
Conditions
SARS-CoV-2
First Posted Date
2023-07-11
Last Posted Date
2023-11-22
Lead Sponsor
AIM Vaccine Co., Ltd.
Target Recruit Count
60
Registration Number
NCT05939596
Locations
🇨🇳

First Affiliated Hospital Bengbu, Bengbu, Anhui, China

Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older

Phase 3
Recruiting
Conditions
SARS-CoV-2
Interventions
Biological: SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
First Posted Date
2023-04-13
Last Posted Date
2023-04-19
Lead Sponsor
AIM Vaccine Co., Ltd.
Target Recruit Count
9800
Registration Number
NCT05812014
Locations
🇵🇰

Sindh Infectious Diseases Hospital & Research Center Dow University of Health Sciences, Islamabad, Pakistan

Clinical Trial of COVID-19 Vaccine(SARS-CoV-2 Variant(Omicron BA.5) mRNA Vaccine) in Participants Aged 18 Years and Over

Not Applicable
Recruiting
Conditions
SARS-CoV-2
Interventions
Biological: SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
Drug: Saline solution
First Posted Date
2023-02-27
Last Posted Date
2023-02-28
Lead Sponsor
AIM Vaccine Co., Ltd.
Target Recruit Count
3200
Registration Number
NCT05745545
Locations
🇨🇳

First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China

A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

Phase 3
Recruiting
Conditions
SARS-CoV-2
First Posted Date
2023-01-12
Last Posted Date
2023-02-21
Lead Sponsor
AIM Vaccine Co., Ltd.
Target Recruit Count
34000
Registration Number
NCT05682638
Locations
🇰🇪

KEMRI CRDR Research Annex, Siaya Country Referral Hospital, Siaya, Kenya

  • Prev
  • 1
  • 2
  • 3
  • Next

News

AIM Vaccine's mRNA RSV Vaccine Advances to U.S. Clinical Trials with Superior Preclinical Results

AIM Vaccine has submitted its novel mRNA RSV vaccine for FDA clinical trials, demonstrating superior humoral and cellular immunity compared to existing marketed products in preclinical studies.

AIM Vaccine's Serum-Free Rabies Vaccine Awaits Global Market Entry

AIM Vaccine Co., Ltd. has pre-applied for marketing approval of its serum-free rabies vaccine, which showed excellent safety and immunogenicity in Phase III trials.

AIM Vaccine Submits 13-Valent Pneumonia Conjugate Vaccine for Approval After Positive Phase III Results

AIM Vaccine Co., Ltd. has submitted its 13-valent pneumonia conjugate vaccine for drug marketing registration to China's National Medical Products Administration.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.